Rigel Pharmaceuticals, Inc.

Investors News & Events Contact Us
  • Home
  • Who We Are
    • Company Overview
    • Management Team
    • Board of Directors
    • Partners
  • Pipeline
    • Pipeline
      • Clinical Trials
      • Investigator Sponsored Research
      • Expanded Access Policy
    • Proprietary Programs
      • Warm AIHA
      • COVID-19
      • IRAK1/4
      • RIPK1
    • Partnered Programs
      • BerGenBio
      • Daiichi-Sankyo
      • Forma
      • Grifols
      • Kissei
      • Lilly
      • Medison
      • Knight
  • Products
  • Join Our Team
    • Life at Rigel
    • Our Values
    • Benefits
    • Current Openings
  • Investors
  • News & Events
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Analyst Coverage
  • Governance
    • Management Team
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • Events & Presentations
  • Email Alerts
Feb 03, 2017 4:01pm EST

Rigel Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Option To Purchase Additional Shares

Jan 31, 2017 7:30am EST

Rigel Announces Pricing Of Public Offering Of Common Stock

Jan 30, 2017 4:01pm EST

Rigel Announces Proposed Public Offering Of Common Stock

Jan 30, 2017 7:30am EST

Fostamatinib Study Results Continue to Trend Positive

Jan 16, 2017 7:30am EST

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jan 05, 2017 7:30am EST

Rigel Provides Business Updates and Preliminary Data in IgA Nephropathy

Nov 10, 2016 7:30am EST

Rigel to Present at Jefferies 2016 London Healthcare Conference

Nov 01, 2016 4:01pm EDT

Rigel Announces Third Quarter 2016 Financial Results and Provides Company Update

Oct 28, 2016 7:30am EDT

Rigel Announces Conference Call and Webcast to Report Third Quarter 2016 Financial Results

Oct 20, 2016 7:00am EDT

Rigel Announces Results from the Second FIT Phase 3 Study and the Long-Term Open-Label Extension Study for Fostamatinib in ITP

  • Previous
  • 1…
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • …36
  • Next
RSS
  • Email Alerts
  • RSS News Feed
Terms of Use Privacy Policy

© 2023 Rigel Pharmaceuticals, Inc. All Rights Reserved.

TAVALISSE, TAVLESSE, RIGEL and the Rigel arc logo are registered trademarks of Rigel Pharmaceuticals, Inc.

REZLIDHIA is a trademark of Rigel Pharmaceuticals, Inc.

Facebook Twitter Linkedin